Nanobiotix Shares Fall 5.65% Mid-Session After Several Days of Strong Gains
The French biotech company takes a breather after an exceptional week that saw it surge over 33% in seven days.
Mid-Day Market Performance
The biotechnology company is currently down 5.65% at 22.55 euros mid-day, after closing at 23.90 euros the previous day. This correction comes amid sustained trading activity, with 1.25% of its capital being traded, a significant level indicating investor interest in the stock. Despite today's decline, the stock has been on a strong upward trajectory in recent weeks: it has gained 33.43% over seven days and an impressive 381.3% over three months. Over the past year, it has risen by 404.5%, significantly outperforming the CAC 40, which has increased by 6.45% over the same period. This correction follows several sessions of strong gains, notably on October 8 when the stock jumped 21.84% to close at 22.20 euros. Today's decline places the price slightly below its recent high of 23.90 euros, now an immediate resistance level. Trading volumes remain high, reflecting both profit-taking after the recent rise and sustained interest in the stock.
Recent Developments Boost Interest
The renewed interest in Nanobiotix can be attributed to several recent announcements. On October 1, the company presented encouraging data from a Phase 1 study evaluating its drug candidate JNJ-1900 (NBTXR3) in patients with esophageal cancer. The results showed an objective response rate of 69% among thirteen patients, with six complete responses and three partial responses, and the treatment was well tolerated. These data, presented at the annual congress of the American Society for Radiation Oncology, were described as promising by analysts at Portzamparc. On October 6, the investment bank Jefferies reaffirmed its buy recommendation on the stock while raising its price target to 21 euros. Analysts acknowledged the stock's strong year-to-date performance, while estimating that it still has potential for further gains, linked to positive publications regarding JNJ-1900 (NBTXR3) applied to various types of solid tumors. This positive outlook contributed to the bullish momentum observed at the beginning of the week.
Technical Analysis Overview
From a technical perspective, the stock is in an area of technical overheating. The relative strength index has reached 95, an extremely high level that typically signals a pronounced overbought condition and may precede a phase of consolidation or correction. Today's decline can thus be interpreted as a breather after a rapid climb. However, the price remains well above its 50-day and 200-day moving averages, which are at 9.91 euros and 5.18 euros respectively, confirming the strength of the underlying bullish trend. The monthly volatility stands at 34.87%, a high level that reflects the magnitude of recent price fluctuations and indicates the speculative nature of the movements. The beta of 0.28 indicates that the stock historically remains less sensitive to fluctuations in the CAC 40 than the market average, although this measure is currently less representative given the exceptional dynamics underway. The Chaikin Money Flow indicator at 0.34 suggests that buying flows remain present despite today's correction, while the MACD, with a line at 3.27 above its signal at 2.30, maintains a bullish signal for the medium term.
